Skip to main content
OpenTrials
Completed

NCT Number: NCT03796286

A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses

This randomized, crossover study will include four clinic visits: one screening (day -7) and three test visits (days 0, 2, 4). The objective of this study is to assess the effects of dietary fiber-containing bars, at two doses of fiber, compared to a control product, on postprandial glucose and insulin responses in healthy adult men and women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MB Clinical Research, Boca Raton, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18-65 y of age, inclusive.
  • Subject has a body mass index of 18.5 to 32.0 kg/m, inclusive.
  • Subject is judged by the Investigator to be in generally good health on the basis of medical history and screening measurements.
  • Subject is willing to consume the study products as described in the protocol.
  • Subject is willing to maintain usual diet and activity patterns throughout the study.
  • Subject has no plans to change smoking or other nicotine use during the study period.
  • Subject is willing and able to attend all clinic visits.
  • Subject has a vein access scale score of 7-10.
  • Subject understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures.

Exclusion criteria

  • Individual has a clinically significant gastrointestinal, endocrine (including Type 1 and Type 2 diabetes mellitus), cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder.
  • Subject has pre-diabetes (fasting capillary glucose between 100 and 125 mg/dL) at screening. One re-test on a separate day will be allowed for subjects with no known history of pre-diabetes or diabetes who have a capillary glucose of 100 - 110 mg/dL at screening (visit 1).
  • Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) at screening.
  • Individual has a history of cancer in the prior 2 years, except for non-melanoma skin cancer.
  • Individual has extreme dietary habits (e.g., Atkins, vegan).
  • Individual has had weight change of ±4.5 kg (10 lbs) in the previous 3 months.
  • Individual has a known allergy, sensitivity, or intolerance to any ingredients in the study products.
  • Individual is a female, who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
  • Individual has been exposed to any non-registered drug product within 30 days of screening.
  • Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.

Treatment and study plan

Medium-fiber bar

Other

Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.

High-fiber bar

Other

Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.

Control bar (0 g fiber)

Other

Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.

Primary outcomes

  1. Change in the incremental area under the curve for capillary glucose.

    Time frame: Up to 120 minutes - measured at each treatment visit

    Differences between the dietary fiber and control conditions following a breakfast meal tolerance test (MTT) completed at visits 2, 3, and 4 in the incremental AUC (iAUC) from pre-breakfast intake to 2 hours post breakfast intake for capillary glucose.

Secondary outcomes

  1. Change in the incremental area under the curve for venous glucose.

    Time frame: Up to 120 minutes - measured at each treatment visit

    Differences between the dietary fiber and control conditions following a breakfast meal tolerance test (MTT) completed at visits 2, 3, and 4 in the incremental AUC (iAUC) from pre-breakfast intake to 2 hours post breakfast intake for venous glucose.

  2. Change in the incremental area under the curve for venous insulin.

    Time frame: Differences between the dietary fiber and control conditions following a breakfast meal tolerance test (MTT) completed at visits 2, 3, and 4 in the incremental AUC (iAUC) from pre-breakfast intake to 2 hours post breakfast intake for venous glucose.

    Differences between the dietary fiber and control conditions following a breakfast meal tolerance test (MTT) completed at visits 2, 3, and 4 in the incremental AUC (iAUC) from pre-breakfast intake to 2 hours post breakfast intake for venous insulin.

Sponsors and collaborators

Lead sponsor

Midwest Center for Metabolic and Cardiovascular Research

Other

Collaborators

  • Ingredion Incorporated

Registry information

Official study title

A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Postprandial Glucose and Insulin Responses.

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jan 8, 2019
Registry last updated
Jul 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.